Better Screening for Liver Cancer with MRI, Researchers Report

Detecting hepatocellular carcinoma in patients with cirrhosis is currently done with ultrasounds given every six months.

Liver cancer is a common outcome for untreated hepatitis C virus infection.

But ultrasound is not sufficiently sensitive to detect early stage cancer, a Korean research team writes in JAMA Oncology.

To improve on that situation, So Yeon Kim, MD, PhD and colleagues at the Liver Center, Asan Medical Center in Seoul tried using MRI scans with liver-specific contrast.

Their study involved 407 patients with cirrhosis and an estimated annual risk of getting liver cancer of greater than 5%.

The patients had one to three biannual screening examinations with paired ultrasound and liver specific contrast enhanced MRI at a tertiary care hospital over a three year period ending in August 2014.

They were followed with dynamic CT scans at six months after the study ended.

Of the patients in the group, 43 had liver cancer at the final screening. One was detected by ultrasound only, 26 by MRI only, 11 by both, and five were missed by both methods.

That meant the MRI had a detection rate of 86.0% compared to 27.9% for the ultrasound approach.

As for false positives, MRI scans had only 3.0% false positives compared to 5.6% for ultrasound. Of the 43 patients with cancer, 32 had very early stage disease, a single nodule of less than 2 cm, and 67.4% were cured with treatment.

The team concluded that in these high risk patients, MRI with liver specific contrast resulted in a higher detection rate and lower false-positive findings compared with ultra sound.

The MRIs also picked up cancer earlier.

“Whether surveillance with MRI would reduce mortality from liver cancer in high-risk patients requires further investigation,” they concluded, but early stage treatment is “associated with a high chance of curative treatments and favorable survival of patients.”

Related Coverage:

Liver Cancer Rising Due to Hepatitis C While Other Cancer Rates Drop

San Francisco on Track to Eliminate Hepatitis C

Eradication of Hepatitis C Dependent on Drug Users' Access to Treatment